Bayer's Lynkuet granted priority review by U.S. FDA for additional indication
September 28, 2026
September 28, 2026
LEVERKUSEN, Germany, Sept. 28 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:
* * *
Bayer's Lynkuet(tm) (elinzanetant) granted priority review by U.S. FDA for additional indication
*
Berlin, September 28, 2026 - Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application (sNDA) and grant . . .
* * *
Bayer's Lynkuet(tm) (elinzanetant) granted priority review by U.S. FDA for additional indication
*
Berlin, September 28, 2026 - Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application (sNDA) and grant . . .